- CST-Therapist Companion sales contract signed with Syddjurs municipality to deliver Cognitive Stimulation Therapy (CST) to people with dementia
- First important repeat sale to Herning who has extended existing contract
- Five 'foot-in-the-door' sales to Danish municipalities so far with a combined value of
DKK 0.25 million - A total of 16 Danish municipalities have started using CST-Therapist Companion to deliver CST; under sales contracts, as participants in a usability study or as partners in the CO-PI grant funded implementation project
- The sales potential for CST-Therapist Companion in
Denmark is estimated atDKK 5-6 million over 1 to 2 years - The Danish sales potential is expected to increase to
DKK 20-25 million , as CST adoption grow - In 2024, Brain+' commercial focus will be on the
UK market, representing a 10x larger dementia market than inDenmark , higher CST adoption rates and established digital therapy reimbursement pathways - CST-Therapist Companion is expected ready for release in the
UK in the 3rd quarter of 2024 with a first sale targeted for end 2024
Brain+ has signed its first sales contract on CST-Therapist Companion with the municipality of Syddjurs. In addition, the sales contract signed with the municipality of Herning in Q1 2023 has been extended, representing the first repeat sale of the product. Including the important reference sales contract closed with the
Brain+ released the first Danish version of CST-Therapist Companion in late 2022 as a digital solution to support care personnel in the municipalities deliver Cognitive Stimulation Therapy (CST) to people with mild to moderate dementia. CST is an evidence based non-pharmaceutical therapy, delivered over 14 sessions to groups of typically 4-8 people with dementia, and which has been shown to delay cognitive decline and improve both social skills and quality of life. CST is recommended by the
CST-Therapist Companion addresses these main barriers for adoption, specifically by reducing preparation time for therapists to allow more face-to-face time with patients, offering consistent CST delivery according to the method, altogether allowing an easier and less resource intensive implementation. The quality assurance of the product instills trust in therapists as the content and methods are developed closely and with strict approval procedures with leading CST experts from the CST inventor
In 2023, Brain+ has in
The five sales contracts on CST, Brain+ has signed so far with Danish municipalities on CST-Therapist Companion cover access to use the product in a select number of dementia care centers, where CST is currently offered. The contracts are considered `foot-in-the-door' sales as a key starting point for Brain+ to establish reference customers and they have a combined value of DKK ~0.25 million. In 2024, Brain+ expects to close new sales contracts with more municipalities and based on the current CST adoption and penetration of digital health products in
As the benefits of CST are gaining more widespread recognition, adoption and penetration of the therapy will grow. Alongside this, the awareness of the value offerings of CST-Therapist Companion is also increasing, which will be supported by medical device certification of the product in 2024. Altogether, these elements are expected to increase the Danish market potential for CST-Therapist Companion alone to
Even if Brain+ is gaining a commercial foothold in
In 3rd quarter of 2024, the company expects to release an English version of CST-Therapist Companion in the
Invitation to investor webinar
Brain+ invites investors to a webinar on Thursday,
----------------------------------------------------------------
Contact Information
CEO and Co-founder:
Brain+ Mission: Bringing effective digitally-delivered dementia therapies to those in need, serving a million people with dementia, care-givers and clinicians by 2030
https://news.cision.com/brain--a-s/r/brain--signs-two-new-danish-sales-contracts-on-cst-therapist-companion-and-updates-on-the-product-s-,c3911539
https://mb.cision.com/Main/20893/3911539/2548465.pdf
https://news.cision.com/brain--a-s/i/1-b-en-rgb,c3258733
(c) 2024 Cision. All rights reserved., source